| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2023 ( Subtotal = $1,126,753 ) |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R44DA059017 | Real World Adoption of an OUD Digital Health Therapeutic | 001 | 1 | NIH | 8/28/2023 | $0 |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R44DA059017 | Real World Adoption of an OUD Digital Health Therapeutic | 002 | 1 | NIH | 9/26/2023 | $0 |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R44DA059017 | Real World Adoption of an OUD Digital Health Therapeutic | 000 | 1 | NIH | 7/24/2023 | $319,543 |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42DA054881 | mHealth for Patient Self-Management of Opioid Use Disorder | 001 | 4 | NIH | 8/17/2023 | $685,922 |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42DA054881 | mHealth for Patient Self-Management of Opioid Use Disorder | 002 | 4 | NIH | 8/30/2023 | $0 |
| | 2023 | 2023 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42DA054881 | mHealth for Patient Self-Management of Opioid Use Disorder | 000 | 3 | NIH | 4/26/2023 | $121,288 |
|
| Issue Date FY: 2022 ( Subtotal = $947,945 ) |
| | 2022 | 2022 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42DA054881 | mHealth for Patient Self-Management of Opioid Use Disorder | 000 | 3 | NIH | 8/10/2022 | $947,945 |
|
| Issue Date FY: 2021 ( Subtotal = $866,907 ) |
| | 2021 | 2021 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42DA054881 | mHealth for Patient Self-Management of Opioid Use Disorder | 000 | 2 | NIH | 8/12/2021 | $866,907 |
| | 2021 | 2018 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R43MH119672 | mHealth for Patient Self-Management of Opioid Use Disorder | 000 | 1 | NIH | 3/25/2021 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $224,959 ) |
| | 2018 | 2018 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R43MH119672 | mHealth for Patient Self-Management of Opioid Use Disorder | 000 | 1 | NIH | 9/14/2018 | $224,959 |
| | 2018 | 2016 | BIOMEDICAL DEVELOPMENT CORPORATION | 499 E HIGH ST #401 | LEXINGTON | KY | 40507-1974 | FAYETTE | USA | R42MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 4 | NIH | 6/22/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $646,204 ) |
| | 2016 | 2016 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R42MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 4 | NIH | 3/23/2016 | $646,204 |
|
| Issue Date FY: 2015 ( Subtotal = $869,569 ) |
| | 2015 | 2015 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R42MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 001 | 3 | NIH | 5/14/2015 | $140,623 |
| | 2015 | 2015 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R42MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 3 | NIH | 4/29/2015 | $728,946 |
|
| Issue Date FY: 2014 ( Subtotal = $0 ) |
| | 2014 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R41MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 2 | NIH | 2/25/2014 | $0 |
|
| Issue Date FY: 2012 ( Subtotal = $907,797 ) |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R41MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 2 | NIH | 2/23/2012 | $245,857 |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R41AG044960 | LONG-TERM BROAD-SPECTRUM PREVENTION OF IMPLANT-RELATED INFECTIONS | 000 | 1 | NIH | 9/20/2012 | $162,266 |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43TR000645 | VESTIBULAR-TOPOGRAPHICAL MEMORY MARKERS FOR THOSE AT RISK FOR ALZHEIMER'S DISEASE | 000 | 1 | NIH | 9/20/2012 | $86,379 |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43TR000645 | VESTIBULAR-TOPOGRAPHICAL MEMORY MARKERS FOR THOSE AT RISK FOR ALZHEIMER'S DISEASE | 000 | 1 | NIH | 9/20/2012 | $111,500 |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43TR000645 | VESTIBULAR-TOPOGRAPHICAL MEMORY MARKERS FOR THOSE AT RISK FOR ALZHEIMER'S DISEASE | 000 | 1 | NIH | 9/20/2012 | $1,880 |
| | 2012 | 2012 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44HL101821 | UNIQUE ANTI-MICROBIAL RINSE TO REDUCE ORAL INFLAMMATION | 000 | 3 | NIH | 6/11/2012 | $299,915 |
|
| Issue Date FY: 2011 ( Subtotal = $250,000 ) |
| | 2011 | 2011 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R41MH091997 | Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder | 000 | 1 | NIH | 3/11/2011 | $250,000 |
| | 2011 | 2010 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44HL101821 | UNIQUE ANTI-MICROBIAL RINSE TO REDUCE ORAL INFLAMMATION | 000 | 2 | NIH | 2/10/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $410,355 ) |
| | 2010 | 2010 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44HL101821 | UNIQUE ANTI-MICROBIAL RINSE TO REDUCE ORAL INFLAMMATION | 001 | 2 | NIH | 8/7/2010 | $410,355 |
| | 2010 | 2009 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44HL101821 | UNIQUE ANTI-MICROBIAL RINSE TO REDUCE ORAL INFLAMMATION | 000 | 1 | NIH | 1/28/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $344,781 ) |
| | 2009 | 2009 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44HL101821 | UNIQUE ANTI-MICROBIAL RINSE TO REDUCE ORAL INFLAMMATION | 000 | 1 | NIH | 8/24/2009 | $344,781 |
|
| Issue Date FY: 2008 ( Subtotal = $333,733 ) |
| | 2008 | 2008 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R41DK082089 | TREATMENT AND/OR PREVENTION OF URINARY TRACT INFECTIONS | 000 | 1 | NIH | 9/15/2008 | $226,733 |
| | 2008 | 2008 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43HD058400 | NOVEL THERAPY TO TREAT OTITIS MEDIA | 000 | 1 | NIH | 5/27/2008 | $107,000 |
|
| Issue Date FY: 2007 ( Subtotal = $356,687 ) |
| | 2007 | 2007 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44DE017301 | NOVEL RINSE TO TREAT ORAL CANDIDIASIS IN CANCER PATIENTS | 000 | 3 | NIH | 8/8/2007 | $356,687 |
|
| Issue Date FY: 2006 ( Subtotal = $638,280 ) |
| | 2006 | 2006 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43AR052544 | NOVEL TOPICAL TREATMENT OF ECZEMA | 000 | 1 | NIH | 8/9/2006 | $134,645 |
| | 2006 | 2006 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R44DE017301 | NOVEL RINSE TO TREAT ORAL CANDIDIASIS IN CANCER PATIENTS | 000 | 2 | NIH | 9/22/2006 | $393,313 |
| | 2006 | 2006 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43AI068375 | NON-TOXIC GEL TO TREAT VULVOVAGINAL CANDIDIASIS | 000 | 1 | NIH | 4/25/2006 | $110,322 |
|
| Issue Date FY: 2005 ( Subtotal = $484,768 ) |
| | 2005 | 2005 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43AR052998 | NOVEL TOPICAL TREATMENT FOR POSTHERPETIC NEURALGIA | 000 | 1 | NIH | 8/26/2005 | $196,914 |
| | 2005 | 2005 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43DE017301 | NOVEL RINSE TO TREAT ORAL CANDIDIASIS IN CANCER PATIENTS | 000 | 1 | NIH | 9/2/2005 | $159,520 |
| | 2005 | 2005 | BIOMEDICAL DEVELOPMENT CORPORATION | PO BOX 6660 | SAN ANTONIO | TX | 78209 | BEXAR | USA | R43AR052213 | NOVEL TOPICAL TREATMENT FOR DISORDERS OF KERATINIZATION | 000 | 1 | NIH | 5/16/2005 | $128,334 |
|
|
